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Aim: To compare the efficiency of extracorporeal shock wave (ESW) treatment with hyaluronic acid (HA) viscosupplementation in an
experimental rabbit cartilage defect model.
Materials and methods: A total of 24 New Zealand rabbits were randomly divided into 4 groups: HA, ESW, ESW + HA, and control.
Chondral defects were created in the left knees of the rabbits. HA viscosupplementation was performed on the HA and ESW + HA
groups, and after 24 h, 0.16 mJ/mm2 ESW was performed on the ESW and ESW + HA groups. After an 8-week follow-up, the rabbits
were sacrificed and histopathological examination of the defects was carried out. In addition, immunohistochemistry was performed
by the avidin-biotin peroxidase method using vascular endothelial growth factor (VEGF), transforming growth factor beta 1 (TGF-β1),
and type II collagen antibodies, and the results were evaluated semiquantitatively.
Results: There was a significant difference between the control group and the ESW group in terms of Pineda score and type II collagen
expression; between the control group and the HA group in terms of Pineda score, VEGF expression, type II collagen expression, and
TGF-β1 expression; and between the control group and the ESW + HA group in terms of Pineda score, VEGF expression, type II
collagen expression, and TGF-β1 expression.
Conclusion: The results show that both treatment methods have positive therapeutic effects on the articular cartilage defect model in
terms of the parameters studied.
Key words: ESW, HA, cartilage defect, VEGF, TGF-β1, type II collagen

1. Introduction
The physical properties of extracorporeal shock wave
(ESW) treatment were first described in 1959 by
Eisenmenger. Shock waves are mainly sound waves.
Approximately 30 years ago, shock waves began to be
applied clinically in various centers in Germany in order to
break up renal stones. In 1980, Chaussy first used ESW in a
human for the purpose of breaking up a kidney stone at the
University of Munich (1). This nonoperative method has
since replaced previous treatments as the gold standard in
the treatment of urinary system stones (1–8).
In the past 20 years, ESW has been used to safely and
effectively to treat various medical conditions (9). ESW is
expanding its applications from urinary calculi treatment
to orthopedic settings such as pseudoarthrosis (10,11),
patellar tendinopathy (12,13), epicondylitis (10,14,15),
plantar fasciitis (10,16), and osteonecrosis (17,18).
* Correspondence: oztemur@cumhuriyet.edu.tr
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Studies conducted in recent times have shown that the
mechanism of ESW can be performed with osteoblastic
and/or angiogenesis-stimulating agents such as
transforming growth factor beta 1 (TGF-β1) and vascular
endothelial growth factor (VEGF). In another study, a
significant increase was identified in colony forming unitosteoprogenitor cells (colony forming unit, CFU-O) and
TGF-β1 quantities as a result of performing ESW in rats
(19–22).
Hyaluronic acid (HA) is an extracellular highmolecular–weight polysaccharide that is a constituent of
many tissues, especially loose connective tissues (23). HA is
the most important glycosaminoglycan of the extracellular
matrix in articular cartilage. It is also responsible for the
viscoelastic properties of synovial fluid. The average
molecular weight in normal healthy people is 4–5 million
daltons. Animal studies have revealed that HA injection
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reduces joint pain and retards the degenerative process.
It is also reported that HA has modulated inflammation,
neutrophile chemotaxis, macrophage proliferation,
phagocytosis, and angiogenesis (24).
The purpose of the present study is to compare the
effects of HA and/or ESW treatment on articular cartilage
defects.
2. Materials and methods
2.1. Animals
The experimental procedures used in this study were
carried out in accordance with guidelines of the National
Institutes of Health regarding the care and use of laboratory
animals. The experimental procedures were approved by
the Institutional Review and Animal Ethics Committee of
Cumhuriyet University Faculty of Medicine, and the study
was conducted according to accepted guidelines on the
care and use of laboratory animals. A total of 24 adult New
Zealand rabbits (Cumhuriyet University Animal Center,
Sivas, Turkey) with an average weight of 2.4 kg were used
in these experiments. Rabbits were randomly divided into
4 groups: control, ESW, HA, and ESW + HA. During the
study, the animals were kept under standardized conditions
and caged individually. They had free access to water, and
a standard pellet diet. Care of all rabbits was provided in
accordance with Animal Care Facility guidelines.
2.2. Preparation of cartilage defects
The animals were induced using ketamine HCl 50 mg/
kg (Ketalar®, Pfizer, Turkey) plus xylazine 6 mg/kg IM
(Rompun®, Bayer, Turkey). During the study, a standard
medial parapatellar approach was used to expose the left
knee. A defect was created in the weight-bearing area of
the medial femoral condyle using a 3-mm drill and incised
until the subchondral layer was seen (Figure 1). Careful
hemostasis and a layered closure were performed to ensure
a watertight seal, and the rabbits were allowed to move
freely in the postoperative period; 4 mg/kg Carprofen
(Rimadyl, Pfizer Inc., UK) was given as postoperative
analgesia for 3 days.
2.3. HA injection
In the HA and ESW + HA groups, 0.3 mL (Orthovisc
15 mg 2 mL ampoule, Anika Therapeutics, Inc., USA)
was injected into the joint after the cartilage defect was
created and the skin was closed. Passive flexion–extension
movements were applied to the knee in order to distribute
the HA homogeneously in the joint.
2.4. ESW procedure
ESW was performed 24 h after the preparation of cartilage
defects using a Storz Masterpuls MP200 device (KARL
STORZ GmbH & Co. KG T, Tuttlingen, Germany). A
1-Hz shockwave at an energy flux density (EFD) of 0.16
mJ/mm2, and 500 impulses, was applied to the left knees of
the rabbits in the ESW and ESW + HA groups. The rabbits

Figure 1. Preparation of cartilage defect.

were anesthetized using injections of ketamine HCl 50
mg/kg (Ketalar®, Pfizer, Turkey) and xylazine 10 mg/kg IM
(Rompun®, Bayer, Turkey).
2.5. Histological evaluation
After the tissues taken were fixed in 10% formaldehyde
solution for 24 h, they were decalcified in 10% formic
acid solution. On macroscopic examination following
decalcification (Figure 2), the sagittal sections taken
passing through the center of the defected regions after
the tissue follow-up procedure were embedded in paraffin.
For morphological examination, 3-μm-thick sections were
taken from the paraffin blocks obtained. Sections stained
with hematoxylin–eosin (H–E), safranine-0, and toluidine
blue were examined using a light microscope. The
safranine-0 and toluidine blue used in the determination of
the quantities of proteoglycan and cartilage were evaluated
semiquantitatively. In the evaluation, the Modified Pineda
(25) Histological Grading Scale was used (Table 1).
2.6. Immunohistochemical method and evaluation
The sections were placed on positively charged slides
and deparaffinized in xylene, and then put into distilled
water after the hydration process. In order to eliminate
endogenous peroxidase activity, 1% hydrogen peroxide
was applied on the sections for 10 min, and then they
were washed with phosphate-buffered saline (PBS).
Antigen retrieval was performed in a microwave for 35
min at high frequency in EDTA (pH 8.4) solution. For
the purpose of reducing nonspecific staining, the sections
were incubated with UV block for 20 min and then with
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Figure 2. White arrows indicate cartilage defects of control and study groups. a. control
group, b. HA group, c. ESW group, d. ESW + HA group.

mouse VEGF (Thermo Scientific, UK), rabbit polyclonal
type II collagen (Novocastra, UK) antibody, and rabbit
polyclonal TGF-β1 (Gene Tex, USA), and for 1.5 h in a
humid environment at 32 °C. Antibody determination
was performed using AEC chromogen (Scytek, USA), and
sections were counterstained with Mayer’s hematoxylin.
After dehydration, they were closed with mounting
medium (Scytek, USA). The sections were examined
under light microscope. In the regenerated tissue, the
expression of VEGF, type II collagen, and TGF-β1 was
evaluated semiquantitatively as no staining (-), weak
staining (+), moderate staining (++), and strong staining
(+++), according to the intensity and extensity of staining.
2.7. Statistical analysis
SPSS 15.0 (SPSS Inc., Chicago, IL, USA) was used to record
and evaluate the results. The distribution and type of data
suggested the use of nonparametric test procedures; thus,
the Kruskal–Wallis test and Mann–Whitney U-test were
used. In the first step, the Kruskal–Wallis test was used to
check the null hypothesis. The null hypothesis was rejected
at a P value of <0.05.
3. Results
During the follow-up, 1 of the rabbits in the HA group
died. The remaining 23 rabbits were included in the
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evaluation. Among all of the groups, there was a
significant difference in terms of VEGF, type II collagen
staining, and Pineda scores (P < 0.05). When the groups
were compared in pairs, a significant difference was found
between the control group and the ESW group in terms
of Pineda score and type II collagen expression (P < 0.05),
and no significant difference was found between them in
terms of VEGF and TGF-β1 expression (P > 0.05). When
the control group and the HA group were compared, a
significant difference was found in terms of Pineda score,
VEGF expression, type II collagen expression, and TGF-β1
expression (P < 0.05). When the control group and ESW
+ HA group were compared, there was a significant
difference in terms of Pineda score, VEGF, type II collagen,
and TGF-β1 expression (P < 0.05). When the ESW group
and the HA group were compared, a significant difference
was found in terms of VEGF and TGF-β1 expression (P <
0.05), but there was no significant difference in terms of
Pineda score and type II collagen expression (P > 0.05).
When the ESW group and the ESW + HA group were
compared, a significant difference was found in terms of
VEGF expression and TGF-β1 expression (P < 0.05), but
there was no significant difference in terms of and type II
collagen expression and Pineda score (P > 0.05). When the
HA and the ESW + HA group were compared, there was
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Table 1. Histological grading scale for the defects of cartilage
(Pineda et al. (14)).
Category

Points

Cell morphology
Hyaline cartilage
Mostly hyaline cartilage
Mostly fibrocartilage
Mostly noncartilage
Noncartilage only
Matrix-staining (metachromasia)
Normal (compared with host adjacent cartilage)
Slightly reduced
Markedly reduced
No metachromatic stain 3
Surface regularitya
Smooth (>3/4)
Moderate (>1/2–3/4)
Irregular (1/4–1/2)
Severely irregular (<1/4)
Thickness of cartilageb
>2/3
1/3–2/3
< 1/3
Integration of donor with host adjacent cartilage
Both edges integrated
One edge integrated
Neither edge integrated
Total maximum

0
1
2
3
4
0
1
2
3
0
1
2
3
0
1
2
0
1
2
14

Total smooth area of the reparative cartilage compared with the
entire area of the cartilage defect.
b
Average thickness of the reparative cartilage compared with that
of the surrounding cartilage.
a

no significant difference in terms of Pineda score,VEGF
expression, type II collagen expression, and TGF-β1
expression (Figure 3–7). The modified Pineda scores,
VEGF, type II collagen, and TGF-β1 expression of the
control and study groups are presented in Table 2.

4. Discussion
HA is a glycosaminoglycan constituent of synovial fluid and
cartilage matrix, and plays an important physiological role
in synovial joints (26–27). Intra-articular hyaluronans have
been approved by the US Food and Drug Administration
(FDA) since 1997 for treating osteoarthritis knee pain, and
there are a number of different hyaluronic acid preparations
for the treatment of knee osteoarthritis (28–30). Positive
effects of HA on repair tissue have been reported in studies
related to chondral defects (31).
Dorotka et al. (32) evaluated the influence of shock
waves on the proliferation of human chondrocytes and
ovine bone marrow stromal cells at EFDs of 0, 0.02,
and 0.06 mJ/mm2 and 0, 500, and 1000 impulses. They
concluded that the proliferation of BMSC increased
under the effect of shock-wave therapy, which provides an
additional explanation for its effectiveness in the treatment
of pseudarthrosis. Such proliferation, however, is not
characteristic of chondrocytes. Chen et al. (22) found
that the expression of TGF-β1 and VEGF-A significantly
increased in femoral defects of rabbits after ESW (EFD of
0.16 mJ/mm2 and 500 impulses). Nishida et al. reported
(33) that a low-level shock wave enhanced the expression of
VEGF and its receptor. Wang et al. (34) reported that in the
repair of full-thickness articular cartilage defects in rabbits,
low-energy shock waves in microfracture holes facilitated
the production of hyaline-like cartilage repair tissues more
than microfracture alone. A clinical study conducted on
long-bone nonunions revealed that shockwave-promoted
bone healing was associated with systemic elevations of
serum NO levels and osteogenic growth factors, including
TGF-β1, VEGF, and bone morphogenetic protein 2
(BMP-2) (35). Another study concluded that ESW has a
chondroprotective effect in subchondral bone remodeling
in the initiation of an osteoarthritis model of the anterior
cruciate ligament of transected knees in rats (36).
Articular cartilage shows only a limited capacity for
repair due to the lack of inherent mechanisms of repair
in mature articular cartilage. Options for the repair or
replacement of focal cartilage lesions include abrasive
chondroplasty, subchondral drilling, and microfracture.
In these procedures, bone marrow-derived stem cells

Table 2. All quantitative data from control and study groups are presented: modified Pineda scores,VEGF expression, type II collagen
expression, and TGF-β1 expression. Data are expressed as mean and standard error of mean.
Control group
(n = 6)

ESW group
(n = 6)

HA group
(n = 5)

ESW + HA group
(n = 6)

3.33 ± 0.52
0.33 ± 0.52
0.50 ± 0.55
0.50 ± 0.84

1.50 ± 0.55 a
0.33 ± 0.52
1.50 ± 0.55 a
0.83 ± 0.41

2.00 ± 0.71a
1.80 ± 0.84a b
2.20 ± 1.10 a
1.80 ± 0.45 a b

1.33 ± 0.52 a
1.17 ± 0.41 a b
1.83 ± 0.75 a
1.50 ± 0.55a b

Modified Pineda score
VEGF
Type II collagen
TGF-β1
a

vs control group; b vs ESW group
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Figure 3. Histological findings using hematoxylin–eosin (a–d) and toluidine blue (e–h) stains. The defect was untreated (control
group) (a–e), treated with ESW (b–f), treated with HA (c–g), and treated with ESW + HA (d–h) (Original magnification ×100).

a

b

c

d

Figure 4. Immunohistochemical staining for VEGF (a–d). The defect was untreated
(control group) (a), treated with ESW (b), treated with HA (c), and treated with ESW +
HA (d) (Original magnification ×100).
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Figure 5. Immunohistochemical staining for type-II collagen (a–d). The defect was untreated (control group) (a), treated with ESW (b),
treated with HA (c), and treated with ESW + HA (d) (Original magnification ×100).
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c
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d

Figure 6. Immunohistochemical staining for TGF-β1 (a–d). The defect was untreated (control group) (a), treated with ESW (b), treated
with HA (c), and treated with ESW + HA group (d). (Original magnification ×100).

(BMSC) are stimulated to migrate from the subchondral
bone to the site of cartilage defect. However, this results
in the formation of fibrocartilage rather than hyaline
cartilage, which contains more fibrous tissue, and has
significantly less proteoglycan and more type I collagen in
terms of biochemistry (37).
The purpose of this study was to determine the
nonsurgical efficiency of HA and ESW in cartilage defects
by comparing the efficiency of ESW and HA without
developing a microfracture in the experimental cartilage

defect model. Among the evaluation parameters of our
study, we used the quantity of type II collagen as well
as tVEGF, TGF-β1, and Pineda score, and we tried to
demonstrate how newly developed cartilage resembles
hyaline cartilage. As a result, it was observed that in both
treatment methods more type II collagen was synthesized
than in the control group. There was no difference in the
quantities of TGF-β1 and VEGF in the ESW group as
compared to the control group. Hausdorf et al. (38) did not
find any significant increase with ESW in TGF-β1 quantity;
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Figure 7. Graphs showing Pineda scores, VEGF staining, type II collagen staining, and TGF-β1 of controls and study groups (*P < 0.05).

however, Wang (21) applied ESW and reported significant
increases depending on dose in samples taken from the
femur distal after bone marrow culture. Although we
applied 500 impulses at 0.16 mJ/mm2 dosage as specified
by Wang, we found no increase in TGF-β1. We think that
this result may be associated with the fact that TGF-β1
evaluation was performed 8 weeks after ESW was carried
out. Furthermore, since we did not apply microfracture
in the subchondral bone, it may be that the migration of
the growth factors, which are thought to be stimulated
in the bone marrow, to the cartilage defect area became
difficult. The advantage of the model used is that ESW
and HA viscosupplementation processes are nonoperative
techniques. Thus, we think that both methods may be used
in treating cartilage defects, and that they may yield better
results if applied in combination with surgical techniques.
In the patient group where HA and ESW techniques were

490

combined, an increase was determined in VEGF and type
II collagen expression. The most important limitations of
the study are a lack of information about when or in which
sessions ESW needs to be applied, and about EFD and
impulse quantity.
In conclusion, we think that both treatment methods
have positive therapeutic effects on articular cartilage in
terms of the parameters studied. Due to its effect on VEGF
and TGF-β1, HA is a better treatment than ESW in EFD
and the impulses studied. In order to evaluate the effect
of ESW on type II collagen synthesis in particular, new
studies should be conducted at different EFD and impulse
quantities.
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